A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Exclusion Criteria

• •1. Symptomatic brain metastasis, leptomeningeal metastasis, spinal cord compression, or primary brain tumor.
• •2. Presence of known coexisting other cancer driver genes.
• •3. Previous or active history of clinically significant cardiovascular dysfunction.
• •4. Presence of active infection.
• •5. History of central nervous system (CNS) diseases.
• •6. Presence of clinically significant interstitial lung disease, radiation pneumonitis, or immune-related pneumonitis requiring treatment.
• •7. Newly diagnosed deep vein thrombosis or pulmonary embolism within 3 months before the first administration of the study treatment.
• •8. Presence of uncontrolled or symptomatic pleural effusion, ascites, or pericardial effusion.
• •9. Having received major surgery within 28 days before the start of the study treatment; having experienced major trauma within 14 days before the start of the study treatment; or planning to undergo major surgery during the study period.
• •10. Having received radiotherapy within 4 weeks before the start of the study treatment, or having received palliative radiotherapy for bone metastatic lesions within 2 weeks before the start of the study treatment.